RENAL CELL CARCINOMA METASTATIC Clinical Trials

33 clinical trials for RENAL CELL CARCINOMA METASTATIC across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial — RECRUITING · NA
• TDM for Optimized Outcome in Patients With mRCC. — RECRUITING
• A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 — RECRUITING · PHASE1
• Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) — RECRUITING · PHASE3
• Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management — RECRUITING · NA
• A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC) — RECRUITING
• A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma — RECRUITING · PHASE1
• A PHASE 2, SINGLE-ARM, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB PLUS LENVATINIB IN PARTICIPANTS WITH FIRST LINE ADVANCED/METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA (NCCRCC) (KEYNOTE-B61) — RECRUITING · PHASE2
• A PHASE III RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) IN COMBINATION WITH AXITINIB VERSUS SUNITINIB MONOTHERAPY AS A FIRST-LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-426) — RECRUITING · PHASE3
• A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA) VERSUS SUNITINIB (SUTENT) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA — RECRUITING · PHASE3
• A MULTI-CENTER, OPEN LABEL, RANDOMIZED PHASE 2 STUDY OF AGS-16C3F VS AXITINIB IN METASTATIC RENAL CELL CARCINOMA — RECRUITING · PHASE2
• A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA — RECRUITING · PHASE3
• High Dose IL-2 in Combination With Anti-PD-1 — TERMINATED · PHASE2
• A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) — ACTIVE_NOT_RECRUITING · PHASE1
• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy — TERMINATED · PHASE3
• A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma — TERMINATED · PHASE1
• Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma — TERMINATED · PHASE2
• Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer — TERMINATED · PHASE2
• Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma — TERMINATED · NA
• Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy — COMPLETED · NA
• Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) — COMPLETED · PHASE2
• A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line — OTHER · PHASE3
• Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC — COMPLETED
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE EFFICACY AND SAFETY OF PEMBROLIZUMAB (MK-3475) PLUS EPACADOSTAT VS STANDARD OF CARE (SUNITINIB OR PAZOPANIB) AS FIRST-LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (MRCC) (KEYNOTE-679/ECHO-302) — COMPLETED · PHASE3
• A RANDOMIZED, PHASE II EFFICACY ASSESSMENT OF MULTIPLE MET KINASE INHIBITORS (CABOZANTINIB [NSC #761968], CRIZOTINIB [NSC #749005], SAVOLITINIB [NSC #785348], AND SUNITINIB [NSC #736511]) IN METASTATIC PAPILLARY RENAL CARCINOMA (PAPMET) — COMPLETED · PHASE2
• A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE-AGENT MLN0128 AND THE COMBINATION OF MLN0128+MLN1117 COMPARED WITH EVEROLIMUS IN THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA THAT HAS PROGRESSED ON VASCULAR ENDOTHELIAL GROWTH FACTOR-TARGETED THERAPY — COMPLETED · PHASE2
• A PHASE 1/1B, OPEN-LABEL, MULTICENTER, REPEAT-DOSE, DOSE-SELECTION STUDY OF CPI-444 AS SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SELECTED INCURABLE CANCERS — COMPLETED · PHASE1
• A PHASE 3, RANDOMIZED, CONTROLLED, MULTI-CENTER, OPEN-LABEL STUDY TO COMPARE TIVOZANIB HYDROCHLORIDE (AV-951) TO SORAFENIB IN SUBJECTS WITH REFRACTORY ADVANCED RENAL CELL CARCINOMA — COMPLETED · PHASE3
• EVALUATION OF TECHNETIUM-99M SESTAMIBI TO DETERMINE MUSCLE ENERGY METABOLISM IN RCC (RENAL CELL CANCER) PATIENTS TREATED WITH SUNITINIB. — NOT_YET_RECRUITING
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB VERUS SUNITINIB MONOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA (CHECKMATE 214, CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVLUATION 214) — COMPLETED · PHASE3
• A CLINICAL TRIAL TO EVALUATE THE EFFECT OF NEOADJUVANT MK-3475 (PEMBROLIZUMAB) THERAPY ON INTRATUMORAL IMMUNE INFILTRATES IN RENAL CELL CANCER (RCC) PATIENTS UNDERGOING SURGICAL RESECTION (KEYNOTE 031) — COMPLETED
• A PHASE II TRIAL TO EVALUATE THE EFFICACY OF AZD6094 (HMPL-504) IN PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA (PRCC). — COMPLETED · PHASE2
• A PHASE 3, RANDOMIZED, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS EVEROLIMUS IN SUBJECTS WITH METASTATIC RENAL CELL CARCINOMA THAT HAS PROGRESSED AFTER PRIOR VEGFR TYROSINE KINASE INHIBITOR THERAPY — COMPLETED · PHASE3

Refine this search